Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate®

Hymenoptera venom immunotherapy: Efficacy, indications, and mechanism of action

David F Graft, MD
Section Editor
David B Golden, MD
Deputy Editor
Anna M Feldweg, MD


Hymenoptera stings can result in life-threatening anaphylaxis, and the most severe reactions can be refractory to single or multiple doses of epinephrine [1,2]. Immunotherapy for venom allergy has been available for over four decades and is highly effective. Unfortunately, many patients with sting-induced allergic reactions are not referred to an allergist/immunologist for evaluation and are never offered this potentially lifesaving therapy [3].

The indications for treatment with venom immunotherapy (VIT) as well as patient selection, effectiveness, and mechanism of action will be reviewed here. Protocols and safety of VIT and the diagnosis of venom allergy are discussed separately. (See "Hymenoptera venom immunotherapy: Technical issues, protocols, adverse effects, and monitoring" and "Diagnosis of Hymenoptera venom allergy".)


A systemic allergic reaction to a sting involves signs and symptoms of immunoglobulin E (IgE)-mediated allergy distant from the site of the sting. In contrast, a local reaction consists of painful swelling and erythema limited to tissues contiguous with the site of the sting. Systemic allergic reactions may range from widespread hives and angioedema (ie, a cutaneous systemic reaction) to anaphylaxis (table 1). Although urticaria/angioedema are generally considered characteristic of an allergic reaction, the absence of urticaria or angioedema during anaphylaxis may be a risk factor for severe anaphylaxis [4].

An understanding of the natural history of venom allergy is critical to the determination of which patients should be treated with VIT. The natural history differs between adults and children (defined in studies as younger than 17 years of age), with adults being at greater overall risk for recurrent systemic reactions. The following generalizations can be made:

In adult patients with past systemic reactions and evidence of venom-specific IgE, the risk of a systemic reaction to a subsequent sting is approximately 35 to 60 percent if VIT is not administered [1,5,6]. Patients with the most severe initial reactions have the highest risk of a recurrence. The variability in reaction rates may arise from differences in Hymenoptera species, the amount of venom delivered during a particular sting, whether the sting was sustained in-hospital or in the field, fluctuations in the patient's immunologic status, or other intrinsic and extrinsic factors [7].


Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Jan 2017. | This topic last updated: Tue Apr 05 00:00:00 GMT 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
  1. Hunt KJ, Valentine MD, Sobotka AK, et al. A controlled trial of immunotherapy in insect hypersensitivity. N Engl J Med 1978; 299:157.
  2. Smith PL, Kagey-Sobotka A, Bleecker ER, et al. Physiologic manifestations of human anaphylaxis. J Clin Invest 1980; 66:1072.
  3. Bilò BM, Bonifazi F. Epidemiology of insect-venom anaphylaxis. Curr Opin Allergy Clin Immunol 2008; 8:330.
  4. Stoevesandt J, Hain J, Kerstan A, Trautmann A. Over- and underestimated parameters in severe Hymenoptera venom-induced anaphylaxis: cardiovascular medication and absence of urticaria/angioedema. J Allergy Clin Immunol 2012; 130:698.
  5. Reisman RE. Natural history of insect sting allergy: relationship of severity of symptoms of initial sting anaphylaxis to re-sting reactions. J Allergy Clin Immunol 1992; 90:335.
  6. van der Linden PW, Hack CE, Struyvenberg A, van der Zwan JK. Insect-sting challenge in 324 subjects with a previous anaphylactic reaction: current criteria for insect-venom hypersensitivity do not predict the occurrence and the severity of anaphylaxis. J Allergy Clin Immunol 1994; 94:151.
  7. Golden DB, Breisch NL, Hamilton RG, et al. Clinical and entomological factors influence the outcome of sting challenge studies. J Allergy Clin Immunol 2006; 117:670.
  8. Lange J, Cichocka-Jarosz E, Marczak H, et al. Natural history of Hymenoptera venom allergy in children not treated with immunotherapy. Ann Allergy Asthma Immunol 2016; 116:225.
  9. Golden DB, Kagey-Sobotka A, Norman PS, et al. Outcomes of allergy to insect stings in children, with and without venom immunotherapy. N Engl J Med 2004; 351:668.
  10. Valentine MD, Schuberth KC, Kagey-Sobotka A, et al. The value of immunotherapy with venom in children with allergy to insect stings. N Engl J Med 1990; 323:1601.
  11. Schuberth KC, Kwiterovich KA, Hagey-Sabotka A. Starting and stopping venom immunotherapy in children with insect allergy. J Allergy Clin Immunol 1988; 81:200 (Abstract).
  12. Golden DBK. Insect allergy. In: Middleton's allergy: Principles and practice, 7th ed, Adkinson NF, Bochner BS, Busse WW, et al (Eds), Mosby, Philadelphia 2009. p.1005.
  13. Goldberg A, Confino-Cohen R. Bee venom immunotherapy - how early is it effective? Allergy 2010; 65:391.
  14. Reisman RE, Dvorin DJ, Randolph CC, Georgitis JW. Stinging insect allergy: natural history and modification with venom immunotherapy. J Allergy Clin Immunol 1985; 75:735.
  15. Graft DF, Schuberth KC, Kagey-Sobotka A, et al. Assessment of prolonged venom immunotherapy in children. J Allergy Clin Immunol 1987; 80:162.
  16. Golden DB, Valentine MD, Kagey-Sobotka A, Lichtenstein LM. Regimens of Hymenoptera venom immunotherapy. Ann Intern Med 1980; 92:620.
  17. Carballada F, Boquete M, Núñez R, et al. Follow-up of venom immunotherapy (VIT) based on conventional techniques and monitoring of immunoglobulin E to individual venom allergens. J Investig Allergol Clin Immunol 2010; 20:506.
  18. Müller U, Thurnheer U, Patrizzi R, et al. Immunotherapy in bee sting hypersensitivity. Bee venom versus wholebody extract. Allergy 1979; 34:369.
  19. Boyle RJ, Elremeli M, Hockenhull J, et al. Venom immunotherapy for preventing allergic reactions to insect stings. Cochrane Database Syst Rev 2012; 10:CD008838.
  20. Brown SG, Wiese MD, Blackman KE, Heddle RJ. Ant venom immunotherapy: a double-blind, placebo-controlled, crossover trial. Lancet 2003; 361:1001.
  21. Müller U, Helbling A, Berchtold E. Immunotherapy with honeybee venom and yellow jacket venom is different regarding efficacy and safety. J Allergy Clin Immunol 1992; 89:529.
  22. Müller U, Berchtold E, Helbling A. Honeybee venom allergy: results of a sting challenge 1 year after stopping successful venom immunotherapy in 86 patients. J Allergy Clin Immunol 1991; 87:702.
  23. Oude Elberink JN, de Monchy JG, Golden DB, et al. Development and validation of a health-related quality-of-life questionnaire in patients with yellow jacket allergy. J Allergy Clin Immunol 2002; 109:162.
  24. Confino-Cohen R, Melamed S, Goldberg A. Debilitating beliefs and emotional distress in patients given immunotherapy for insect sting allergy: a prospective study. Allergy Asthma Proc 2009; 30:546.
  25. Oude Elberink JN, De Monchy JG, Van Der Heide S, et al. Venom immunotherapy improves health-related quality of life in patients allergic to yellow jacket venom. J Allergy Clin Immunol 2002; 110:174.
  26. Golden DB, Moffitt J, Nicklas RA, et al. Stinging insect hypersensitivity: a practice parameter update 2011. J Allergy Clin Immunol 2011; 127:852.
  27. Joint Task Force on Practice Parameters, American Academy of Allergy, Asthma and Immunology, American College of Allergy, Asthma and Immunology, Joint Council of Allergy, Asthma and Immunology. Allergen immunotherapy: a practice parameter second update. J Allergy Clin Immunol 2007; 120:S25.
  28. Bonifazi F, Jutel M, Biló BM, et al. Prevention and treatment of hymenoptera venom allergy: guidelines for clinical practice. Allergy 2005; 60:1459.
  29. Ruëff F, Bilò MB, Jutel M, et al. Sublingual immunotherapy with venom is not recommended for patients with Hymenoptera venom allergy. J Allergy Clin Immunol 2009; 123:272.
  30. Patriarca G, Nucera E, Roncallo C, et al. Sublingual desensitization in patients with wasp venom allergy: preliminary results. Int J Immunopathol Pharmacol 2008; 21:669.
  31. Golden DB, Marsh DG, Kagey-Sobotka A, et al. Epidemiology of insect venom sensitivity. JAMA 1989; 262:240.
  32. Reisman RE. Insect stings. N Engl J Med 1994; 331:523.
  33. Lockey RF, Turkeltaub PC, Baird-Warren IA, et al. The Hymenoptera venom study I, 1979-1982: demographics and history-sting data. J Allergy Clin Immunol 1988; 82:370.
  34. Valentine MD. Insect-sting anaphylaxis. Ann Intern Med 1993; 118:225.
  35. Müller UR. Bee venom allergy in beekeepers and their family members. Curr Opin Allergy Clin Immunol 2005; 5:343.
  36. Schwartz HJ, Golden DB, Lockey RF. Venom immunotherapy in the Hymenoptera-allergic pregnant patient. J Allergy Clin Immunol 1990; 85:709.
  37. Pitsios C, Demoly P, Bilò MB, et al. Clinical contraindications to allergen immunotherapy: an EAACI position paper. Allergy 2015; 70:897.
  38. Tunon-de-Lara JM, Villanueva P, Marcos M, Taytard A. ACE inhibitors and anaphylactoid reactions during venom immunotherapy. Lancet 1992; 340:908.
  39. Ober AI, MacLean JA, Hannaway PJ. Life-threatening anaphylaxis to venom immunotherapy in a patient taking an angiotensin-converting enzyme inhibitor. J Allergy Clin Immunol 2003; 112:1008.
  40. Ruëff F, Przybilla B, Biló MB, et al. Predictors of severe systemic anaphylactic reactions in patients with Hymenoptera venom allergy: importance of baseline serum tryptase-a study of the European Academy of Allergology and Clinical Immunology Interest Group on Insect Venom Hypersensitivity. J Allergy Clin Immunol 2009; 124:1047.
  41. Rank MA, Oslie CL, Krogman JL, et al. Allergen immunotherapy safety: characterizing systemic reactions and identifying risk factors. Allergy Asthma Proc 2008; 29:400.
  42. White KM, England RW. Safety of angiotensin-converting enzyme inhibitors while receiving venom immunotherapy. Ann Allergy Asthma Immunol 2008; 101:426.
  43. Cox L, Nelson H, Lockey R, et al. Allergen immunotherapy: a practice parameter third update. J Allergy Clin Immunol 2011; 127:S1.
  44. Caviglia AG, Passalacqua G, Senna G. Risk of severe anaphylaxis for patients with Hymenoptera venom allergy: Are angiotensin-receptor blockers comparable to angiotensin-converting enzyme inhibitors? J Allergy Clin Immunol 2010; 125:1171; author reply 1171.
  45. Müller UR, Haeberli G. Use of beta-blockers during immunotherapy for Hymenoptera venom allergy. J Allergy Clin Immunol 2005; 115:606.
  46. Stoevesandt J, Hosp C, Kerstan A, Trautmann A. Hymenoptera venom immunotherapy while maintaining cardiovascular medication: safe and effective. Ann Allergy Asthma Immunol 2015; 114:411.
  47. Graft DF, Schuberth KC, Kagey-Sobotka A, et al. A prospective study of the natural history of large local reactions after Hymenoptera stings in children. J Pediatr 1984; 104:664.
  48. Mauriello PM, Barde SH, Georgitis JW, Reisman RE. Natural history of large local reactions from stinging insects. J Allergy Clin Immunol 1984; 74:494.
  49. Golden DB, Kelly D, Hamilton RG, Craig TJ. Venom immunotherapy reduces large local reactions to insect stings. J Allergy Clin Immunol 2009; 123:1371.
  50. Mosbech H, Frew AJ. The immunologic response to Hymenoptera venoms. In: Monograph on insect allergy, 4th ed, Levine MI, Lockey RF (Eds), American Academy of Allergy Asthma and Immunology, Milwaukee 2003. p.75.
  51. Dreschler K, Bratke K, Petermann S, et al. Impact of immunotherapy on blood dendritic cells in patients with Hymenoptera venom allergy. J Allergy Clin Immunol 2011; 127:487.
  52. Kerstan A, Albert C, Klein D, et al. Wasp venom immunotherapy induces activation and homing of CD4(+)CD25(+) forkhead box protein 3-positive regulatory T cells controlling T(H)1 responses. J Allergy Clin Immunol 2011; 127:495.
  53. Varga EM, Francis JN, Zach MS, et al. Time course of serum inhibitory activity for facilitated allergen-IgE binding during bee venom immunotherapy in children. Clin Exp Allergy 2009; 39:1353.
  54. Jutel M, Akdis M, Blaser K, Akdis CA. Are regulatory T cells the target of venom immunotherapy? Curr Opin Allergy Clin Immunol 2005; 5:365.
  55. Lessof MH, Sobotka AK, Lichtenstein LM. Effects of passive antibody in bee venom anaphylaxis. Johns Hopkins Med J 1978; 142:1.
  56. Golden DB, Lawrence ID, Hamilton RH, et al. Clinical correlation of the venom-specific IgG antibody level during maintenance venom immunotherapy. J Allergy Clin Immunol 1992; 90:386.
  57. McHugh SM, Deighton J, Stewart AG, et al. Bee venom immunotherapy induces a shift in cytokine responses from a TH-2 to a TH-1 dominant pattern: comparison of rush and conventional immunotherapy. Clin Exp Allergy 1995; 25:828.
  58. Jutel M, Pichler WJ, Skrbic D, et al. Bee venom immunotherapy results in decrease of IL-4 and IL-5 and increase of IFN-gamma secretion in specific allergen-stimulated T cell cultures. J Immunol 1995; 154:4187.
  59. Pereira-Santos MC, Baptista AP, Melo A, et al. Expansion of circulating Foxp3+)D25bright CD4+ T cells during specific venom immunotherapy. Clin Exp Allergy 2008; 38:291.
  60. Nasser SM, Ying S, Meng Q, et al. Interleukin-10 levels increase in cutaneous biopsies of patients undergoing wasp venom immunotherapy. Eur J Immunol 2001; 31:3704.